NCT03119805 (ReFlaP) is a clinical trial in Psoriatic Arthritis, sponsored by Groupe Hospitalier Pitie-Salpetriere.

Who is sponsoring NCT03119805?

NCT03119805 is sponsored by Groupe Hospitalier Pitie-Salpetriere.

What condition does NCT03119805 study?

NCT03119805 studies Psoriatic Arthritis.

Is NCT03119805 still recruiting?

NCT03119805 is currently completed. Last updated 17 October 2018.

Last reviewed 2018-10-17 · How we verify

NCT03119805: ReFlaP

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Remission and Flare in Psoriatic Arthritis: a Prospective 6-month Study With a Double Perspective.

Completed Last updated 17 October 2018

What this trial tests

trial in Psoriatic Arthritis in 466 participants. Completed in 30 July 2018.

Timeline

18 May 2017

Primary endpoint
30 January 2018

30 July 2018

Quick facts

Lead sponsor	Groupe Hospitalier Pitie-Salpetriere
Status	Completed
Study type	OBSERVATIONAL
Enrollment	466
Start date	18 May 2017
Primary completion	30 January 2018
Estimated completion	30 July 2018
Sites	22 locations across France, Italy, Russia, Austria, Estonia, United Kingdom, Germany, Romania

Conditions studied

Psoriatic Arthritis — all drugs for Psoriatic Arthritis →

Sponsor

Groupe Hospitalier Pitie-Salpetriere

Who can join

18 and older, any sex, with Psoriatic Arthritis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to define cut-off values of the most widely used composite scores and patient-reported outcomes, for levels corresponding to remission/low disease activity and for changes in levels corresponding to flares, in PsA, when remission/low disease activity and flare are defined from the patient and physician perspective. The ReFlaP (Remission/Flare in PsA) study is a prospective, multicentric international, longitudinal, observational study.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Comparing patient-perceived and physician-perceived remission and low disease activity in psoriatic arthritis: an analysis of 410 patients from 14 countries.
Gorlier C, Orbai AM, Puyraimond-Zemmour D, Coates LC, et al · · 2019 · cited 45× · PMID 30442648 · DOI 10.1136/annrheumdis-2018-214140
Determinants of Patient-Reported Psoriatic Arthritis Impact of Disease: An Analysis of the Association With Sex in 458 Patients From Fourteen Countries.
Orbai AM, Perin J, Gorlier C, Coates LC, et al · · 2020 · cited 31× · PMID 31609525 · DOI 10.1002/acr.24090
Determinants of sleep impairment in psoriatic arthritis: An observational study with 396 patients from 14 countries.
Palominos PE, Coates L, Kohem CL, Orbai AM, et al · · 2020 · cited 12× · PMID 32283280 · DOI 10.1016/j.jbspin.2020.03.014
Association between obesity and likelihood of remission or low disease activity status in psoriatic arthritis applying index-based and patient-based definitions of remission: a cross-sectional study.
Leung YY, Eder L, Orbai AM, Coates LC, et al · · 2023 · cited 10× · PMID 37709527 · DOI 10.1136/rmdopen-2023-003157
Comparing the Patient-Reported Physical Function Outcome Measures in a Real-Life International Cohort of Patients With Psoriatic Arthritis.
Leung YY, Orbai AM, de Wit M, Balanescu A, et al · · 2021 · cited 9× · PMID 31961492 · DOI 10.1002/acr.24139
What influences patients' opinion of remission and low disease activity in psoriatic arthritis? Principal component analysis of an international study.
Coates LC, Robinson DE, Orbai AM, Kiltz U, et al · · 2021 · cited 7× · PMID 33751029 · DOI 10.1093/rheumatology/keab220
Patient-defined flares and disease activity worsening in 222 patients with psoriatic arthritis from 14 countries.
Sousa M, Lubrano E, Smolen JS, Gorlier C, et al · · 2023 · cited 5× · PMID 36529417 · DOI 10.1016/j.jbspin.2022.105511
Disparities in healthcare in psoriatic arthritis: an analysis of 439 patients from 13 countries.
Lucasson F, Kiltz U, Kalyoncu U, Leung YY, et al · · 2022 · cited 5× · PMID 35523519 · DOI 10.1136/rmdopen-2021-002031

Verify or expand the search:

Other recruiting trials for Psoriatic Arthritis

Currently open trials in the same condition.

NCT07286058 — Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis · Phase 3 · recruiting
NCT07295509 — A Study of Picankibart in Patients With Active Psoriatic Arthritis · Phase 2, PHASE3 · recruiting
NCT07290036 — A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adu · Phase 1 · recruiting
NCT07180537 — Creating Health Course Study for People With Rheumatological Conditions · NA · recruiting
NCT06888193 — A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® · Phase 1 · recruiting

Other Groupe Hospitalier Pitie-Salpetriere trials

Trials by the same sponsor.

NCT06515678 — Impact of Antihypertensive Therapy on Recurrence Risk of Ovarian Cancer for Bevacizumab-associated Hypertension · active not recruiting
NCT05934214 — EXploring Immune-related Adverse Events of Immune checkpoinT Inhibitors Using VigiBase, the WHO Pharmacovigilance Databa · completed
NCT05819736 — Pharmacokinetics Study Of Rivaroxaban and Apixaban in Cancer Patients · unknown
NCT04320017 — Joint Use of Electrocardiogram and Transthoracic Echocardiography With Other Clinico-biological Parameters in an Observa · completed
NCT04314817 — Adverse Events Related to Treatments Used Against Coronavirus Disease 2019 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03119805 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Groupe Hospitalier Pitie-Salpetriere
Last refreshed: 17 October 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03119805.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing